Zymeworks Inc.
NYSE:ZYME
Overview | Financials
Company Name | Zymeworks Inc. |
Symbol | ZYME |
Currency | USD |
Price | 16.77 |
Market Cap | 1,155,075,675 |
Dividend Yield | 0% |
52-week-range | 6.83 - 17.25 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Kenneth H. Galbraith C.A. |
Website | https://www.zymeworks.com |
An error occurred while fetching data.
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD